Scientists have uncovered new genetic rules that determine whether the immune system’s “killer” T cells remain powerful long-term defenders or become worn out and ineffective. By building a detailed ...

As populations age worldwide, the decline of the immune system, a process known as immunosenescence, has become a critical ...

Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a game plan, and coordinate their defenses in lymphoid organs. Researchers have ...

Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

As people age, their immune system function declines. T cell populations become smaller and can’t react to pathogens as quickly, making individuals more susceptible to a variety of infections. To try ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

Over the past few decades, the idea of modifying a patient’s own immune cells to recognize and destroy cancer has evolved from concept to reality. So-called “adoptive T cell therapy” has emerged as ...

Immunotherapy has transformed cancer care, offering a way to harness the body’s own immune system to fight tumors. But even with these advances, many patients still don’t respond. One major barrier to ...

Germline Pathogenic/Likely Pathogenic Mutations and Subsequent Neoplasms Among Childhood Cancer Survivors: A Report From the Children's Oncology Group ALTE03N1 Study Patients received escalating ...